Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23K—FODDER
  • A23K20/00—Accessory food factors for animal feeding-stuffs
  • A23K20/10—Organic substances
  • A23K20/195—Antibiotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
  • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/15—Depsipeptides; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Definitions

• the present invention relates to a mixture comprising virginiamycin.
• Virginiamycin antibiotics in their most effective form, include both M and S components. Coccito, Micro. Rev.. 43, 145 (1979). Virginiamycin has been used as an antibacterial and in the prevention of lacti ⁇ acidosis (e.g. United States Patents 5,137,900 and 5,242,938 and The Merck Index, 12th Edition, pages 1707-1708). It has also been used in the form of a feed additive to improve growth in poultry, swine, and cattle. A possible mechanism for its use as a growth promotant could relate to an inhibition of intestinal flora. Coccito, supra. Virginiamycin's widely accepted use stems from having low toxicity, minimal production of resistant mutant strains, quick degradation in feces, and minimal tissue retention.
• Wettable powders have been used for the administration of various insecticides and herbicides.
• the present invention relates to a mixture comprising: a) virginiamycin; b) a pharmaceutically acceptable surfactant including sodium lauryl sulfate; c) a sufficient amount of pharmaceutically acceptable buffering agent to provide a pH of from about 3.0 to about 7.0 when said mixture is added to water; and d) from about 0.5 weight percent to about 10.0 weight percent colloidal silicon dioxide, wherein the ratio of the weight percent of (b) to the weight percent of (a) is at least about 1.5:1.
• the mixture comprising virginiamycin is in the form of a wettable-type powder.
• the powder mixture can be added to water, including some forms of hard water, to produce a stable suspension of the virginiamycin, which can then be, for example, delivered directly to a patient (e.g orally) or applied to, for example, food stuffs such as feed grain.
• the feed grain is then fed to animals, for example livestock and poultry, thereby administering the virginiamycin.
• the mixture should preferably be substantially anhydrous so as to maximize the shelf life of the mixture prior to forming the water suspension.
• Virginiamycin can be produced using known methods, for example, fermentation.
• virginiamycin M can be produced by fermentation of a streptomyces species originally isolated from Indian soil samples and deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, United States of America on July 29, 1986 and assigned ATCC number 53527, United States Patent 5,242,938.
• Dose levels of virginiamycin are known in the art and can vary due to a number of factors, including, for example, compound activity, the route of administration, the time of administration, disease severity, excretion rate, combination of other drugs, as well as the age, body weight, sex, diet, and general health of the patient being treated.
• the daily effective dose can range from about 1.0 mg to about 500 mg, preferably about 10 mg to about 500 mg, in single or divided doses.
• the effective dose can range from about 5 to about 200 parts per million per volume of food. United States Patent 5,242,938.
• the claimed mixture comprises virginiamycin, preferably substantially pure, and a pharmaceutically acceptable surfactant, sodium lauryl sulfate (SLS), preferably substantially anhydrous and granulated.
• SLS sodium lauryl sulfate
• the ratio of the weight percent of SLS to the weight percent of virginiamycin should be at least about 1.5 to 1 , preferably about 1.54 to 1.
• Substantially pure virginiamycin has an activity of about 200% (plus or minus 20%) as measured by methods known in the art (Gossele, et al., Analyst. 116, 1373 (1991) and Blain, et al., Analyst. 119. 361 (1994).
• the powder mixture also includes a pharmaceutically acceptable anti-caking agent, colloidal silicon dioxide, which can act as scavenger for water as well as a wetting and suspending agent for the virginiamycin.
• colloidal silicon dioxide can range from 0.5 weight percent of the mixture to about 10.0 weight percent of the mixture, preferably about 2.0 weight percent.
• a pharmaceutically acceptable buffer is also included, for example phosphate or citrate buffers, preferably citric acid/sodium citrate.
• the amount of buffer should be sufficient to provide a pH of from about 3.0 to about 7.0, preferably from about 4.0 to about 5.5 when the mixture is added to water. Maintenance of pH permits the virginiamycin to be suspended in a water environment with minimal effect on its activity.
• the powder mixture is added to water to form a stable suspension of the virginiamycin, which is then applied to, for example, feed grain.
• the amount of mixture dispensed in the water is approximately 4.5% by weight of the suspension.
• a pharmaceutically acceptable water soluble filler material can also be included.
• examples include sugars, such as lactose and dextrose, preferably lactose. Such fillers may also effect the flowability of the mixture.
• a pharmaceutically acceptable anti-foaming agent which is, for example, an emulsion and will not substantially effect the pH of the resulting suspension, can also be included in the anhydrous mixture, for example, polydimethylsiloxane. Once the suspension is made, the anti-foaming agent minimizes the amount of foam caused by the SLS upon agitation of the suspension. This can be important if, for example, the suspension is being sprayed and a pump is needed to drive the suspension through the spraying apparatus.
• the amount of anti-foaming agent in the mixture can range from about 0.5 weight percent to about 10.0 weight percent, preferably about 2.8 weight percent.
• the mixture should preferably be maintained as substantially anhydrous prior to forming the suspension in order to minimize the breakdown of the components of the mixture. As a result of minimizing breakdown, the shelf life of the mixture can be maximized.
• the mixture is formed by adding its ingredients together and thoroughly blending them together. Once the mixture is formed, a suspension can be made by adding the mixture to water. The resulting suspension is substantially stable with minimal sedimentation of virginiamycin falling out of the suspension for about a day with periodic stirring or with little or no stirring of the suspension for about a couple hours, preferably about six hours once the suspension has been properly formed.
• a pharmaceutically acceptable indicator dye can also be included, depending upon acceptable food and drug regulations.
• the dye for example, FD&C blue No. 1 powder, would give a blue color to the suspension and, in turn, to feed grain sprayed therewith. Thus, the treated grain can be readily identified.
• a preferred formulation of the claimed invention is the following: INGREDIENT FORMULA % w/w
• Citric Acid anhydrous, fine granular C 6 H,O 7 20.0
• Example 1 The below listed ingredients were combined and mixed together until a uniform mixture was formed.
• a suspension was formed by adding the above mixture to 900 ml of distilled water in a 1 liter graduated cylinder until dispersion was complete. Then additional water was added to bring the total volume to 1 liter. pH 4.24.
• Example 2 The below listed ingredients were combined and mixed together until a uniform mixture was formed
• a suspension was formed by adding the above mixture to 900 ml of distilled water in a 1 liter graduate until dispersion was complete. Then additional water was added to bring the total volume to 1 liter. pH 4.30.
• Example 3

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Polymers & Plastics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Husbandry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Immunology (AREA)
• Organic Chemistry (AREA)
• Food Science & Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Fodder In General (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Child Applications (1)

Publications (1)

Family

ID=21799022

Family Applications (2)

Family Applications After (1)

Country Status (15)

Families Citing this family (4)

Family Cites Families (6)

• 1997
  • 1997-06-05 WO PCT/IB1997/000643 patent/WO1998000136A1/en active IP Right Grant
  • 1997-06-05 CA CA002259298A patent/CA2259298A1/en not_active Abandoned
  • 1997-06-05 BR BR9710019A patent/BR9710019A/pt not_active Application Discontinuation
  • 1997-06-05 TR TR1998/02741T patent/TR199802741T2/xx unknown
  • 1997-06-05 NZ NZ333301A patent/NZ333301A/en unknown
  • 1997-06-05 JP JP10503938A patent/JPH11514001A/ja not_active Ceased
  • 1997-06-05 KR KR10-1998-0710879A patent/KR100395607B1/ko not_active IP Right Cessation
  • 1997-06-05 IL IL12756597A patent/IL127565A0/xx unknown
  • 1997-06-05 PL PL97330961A patent/PL330961A1/xx unknown
  • 1997-06-05 EP EP97922002A patent/EP0906098A1/de not_active Withdrawn
  • 1997-06-05 EP EP01118965A patent/EP1147770A1/de not_active Withdrawn
  • 1997-06-05 AU AU27862/97A patent/AU2786297A/en not_active Abandoned
  • 1997-06-26 AP APAP/P/1997/001038A patent/AP9701038A0/en unknown
  • 1997-06-30 MA MA24696A patent/MA24239A1/fr unknown
  • 1997-06-30 ZA ZA975805A patent/ZA975805B/xx unknown
  • 1997-06-30 DZ DZ970106A patent/DZ2256A1/fr active
• 2002
  • 2002-03-07 JP JP2002061618A patent/JP2002316931A/ja not_active Ceased

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events